Lukas C. Amler

13.8k total citations · 3 hit papers
98 papers, 9.5k citations indexed

About

Lukas C. Amler is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lukas C. Amler has authored 98 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 41 papers in Molecular Biology and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lukas C. Amler's work include HER2/EGFR in Cancer Research (28 papers), Lung Cancer Treatments and Mutations (19 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Lukas C. Amler is often cited by papers focused on HER2/EGFR in Cancer Research (28 papers), Lung Cancer Treatments and Mutations (19 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Lukas C. Amler collaborates with scholars based in United States, Germany and United Kingdom. Lukas C. Amler's co-authors include Mark R. Lackner, Manfred Schwab, Thomas Januario, Somasekar Seshagiri, Elizabeth A. Punnoose, Jeremy Stinson, Guy Cavet, Carol O’Brien, Garret M. Hampton and David A. Eberhard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Lukas C. Amler

97 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 1.2k citations Lukas C. Amler, Sherry Heldens et al. Journal of Clinical Oncology profile →
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

2005 613 citations Lukas C. Amler et al. profile →
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2010 568 citations Hope S. Rugo, Ian E. Krop et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Lukas C. Amler

Since Specialization

Citations

This map shows the geographic impact of Lukas C. Amler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lukas C. Amler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lukas C. Amler more than expected).

Fields of papers citing papers by Lukas C. Amler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lukas C. Amler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lukas C. Amler. The network helps show where Lukas C. Amler may publish in the future.

Co-authorship network of co-authors of Lukas C. Amler

This figure shows the co-authorship network connecting the top 25 collaborators of Lukas C. Amler. A scholar is included among the top collaborators of Lukas C. Amler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lukas C. Amler. Lukas C. Amler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib 2017 ·Clinical Cancer Research ·Matthew Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey A. Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas C. Amler, Yibing Yan, Antoni Ribas	28
2	Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC 2016 ·Annals of Oncology ·Marcin Kowanetz, Wei Zou, David S. Shames, (unknown), Naiyer A. Rizvi, Alexander I. Spira, Garrett M. Frampton, Vincent Lévêque, Shannon L. Flynn, Simonetta Mocci, G. Shankar, Roel Funke, M. Ballinger, Daniel Waterkamp, A. Sandler, Garret M. Hampton, Lukas C. Amler, Priti S. Hegde, Matthew D. Hellmann	34
3	Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer 2015 ·Clinical Cancer Research ·Lisa Ryner, Yinghui Guan, Ron Firestein, Yuanyuan Xiao, (unknown), Christina Rabe, Shan Lu, (unknown), Ling‐Yuh Huw, Mark R. Lackner, Ling Fu, Lukas C. Amler, Carlos Bais, Yulei Wang	86
4	High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing 2014 ·Clinical Cancer Research ·Richard Bourgon, Shan Lu, Yibing Yan, Mark R. Lackner, Weiru Wang, Victor Weigman, David Wang, Yinghui Guan, Lisa Ryner, Hartmut Koeppen, Rajesh Patel, Garret M. Hampton, Lukas C. Amler, Yulei Wang	52
5	Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation 2012 ·Cancer Research ·Shyhmin Huang, Chunrong Li, Eric A. Armstrong, Chimera R. Peet, Jarob Saker, Lukas C. Amler, Mark X. Sliwkowski, Paul M. Harari	150
6	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib 2012 ·Clinical Cancer Research ·Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M. Fine, Brett Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, Mark R. Lackner	341
7	DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Walter Kim, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, (unknown), Leonardo Iniguez, Robert Soriano, Ling Huw, Howard M. Stern, Zora Modrušan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yauch, David S. Shames	66
8	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models 2012 ·Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner	149
9	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors 2012 ·Molecular Cancer Therapeutics ·Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John G. Moffat, Marcia Belvin, Mark R. Lackner	155
10	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine 2012 ·Journal of Clinical Oncology ·Ian E. Krop, Patricia LoRusso, Kathy D. Miller, Shanu Modi, Denise A. Yardley, Gladys Rodriguez, Ellie Guardino, Michael W. Lu, (unknown), Sandhya Girish, Lukas C. Amler, Eric P. Winer, Hope S. Rugo	274
11	Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib 2011 ·Clinical Cancer Research ·Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine	106
12	Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab 2010 ·Clinical Cancer Research ·Howard M. Stern, (unknown), Klaus W. Wagner, Lukas C. Amler, Avi Ashkenazi	33
13	In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models 2009 ·Clinical Cancer Research ·Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth A. Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	385
14	Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer 2009 ·Molecular Cancer Therapeutics ·Jiping Zha, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Fiona Zhong, Leanne Berry, Gail D. Lewis Phillips, Elizabeth Luis, Guy Cavet, Xiaolan Hu, Lukas C. Amler, Mark R. Lackner	66
15	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes 2009 ·Molecular Cancer Research ·Xiaolan Hu, Howard M. Stern, Lin Ge, Carol O’Brien, Lauren E. Haydu, (unknown), Peter M. Haverty, Brock A. Peters, Thomas D. Wu, Lukas C. Amler, John Chant, David Stokoe, Mark R. Lackner, Guy Cavet	177
16	Abstract #LB-131: Biomarker evaluation in the Phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes 2009 ·Cancer Research ·Roy S. Herbst, Howard M. Stern, Lukas C. Amler, Gregory A. Otterson, Ming Lin, Paula G. O’Connor, John D. Hainsworth	1
17	Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays 2008 ·Molecular Cancer Therapeutics ·Zachary Boyd, Qun Wu, Carol O’Brien, Jill M. Spoerke, Heidi Savage, Paul J. Fielder, Lukas C. Amler, Yibing Yan, Mark R. Lackner	51
18	Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer 2006 ·Cancer Research ·Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu, Christophe Severin, Linda Rangell, Ralph Schwall, Lukas C. Amler, Dineli Wickramasinghe, Robert L. Yauch	372
19	Human homologue of a candidate for the Mom1 locus, the secretory type II phospholipase A2 (PLA2S-II), maps to 1p35-36.1/D1S199. 1995 ·PubMed ·Christian Praml, Larissa Savelyeva, Denis Le Paslier, Linda D. Siracusa, Arthur M. Buchberg, Manfred Schwab, Lukas C. Amler	24
20	Neuroblastoma consensus deletion maps to 1p36.1–2 1989 ·Genes Chromosomes and Cancer ·Andreas Weith, Tommy Martinsson, Celina Cziepluch, Silke Brüderlein, Lukas C. Amler, Frank Berthold, Manfred Schwab	146

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact